Cerivastatin (sodium salt)

Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Ki = 1.3 nM). It inhibits cholesterol synthesis in and growth of human arterial myocytes (IC50s = 0.4 and 4.6 nM, respectively). Cerivastatin inhibits proliferation of rat aorta smooth muscle cells and reduces fibrinogen-induced migration of rat aortic myocytes in a concentration-dependent manner. In vivo, cerivastatin inhibits cholesterol biosynthesis in rats and dogs (ED50 = 0.002 mg/kg for both). It reduces serum levels of cholesterol, triglycerides, and low-density lipoprotein (LDL) in dogs in a dose-dependent manner. Cerivastatin (0.1 mg/kg) decreases cholesterol ester accumulation in arterial tissue of rabbits fed a 0.2% cholesterol diet. It also stabilizes plaques and delays progression into atherosclerotic disease in LDL-receptor deficient rabbits with hypercholesterolemia.Formal Name: (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid, monosodium salt. CAS Number: 143201-11-0. Synonyms: BAY-w 6228. Molecular Formula: C26H33FNO5 . Na. Formula Weight: 481.5. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 10 mg/ml, DMSO: 10 mg/ml, Ethanol: 0.5 mg/ml, PBS (pH 7.2): 0.2 mg/ml. SMILES: FC1=CC=C(C2=C(COC)C(C(C)C)=NC(C(C)C)=C2/C=C/[C@@H](O)C[C@@H](O)CC([O-])=O)C=C1.[Na+]. InChi Code: InChI=1S/C26H34FNO5.Na/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4,/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32),/q,+1/p-1/b11-10+,/t19-,20-,/m1./s1. InChi Key: GPUADMRJQVPIAS-QCVDVZFFSA-M.